Previous studies have reported similar findings, showing that albumin therapy improved the 7-day survival rate in cirrhosis patients with sepsis (Philips et al., 2021), but did not lead to improved 28-day survival rates (Maiwall et al., 2022). This evidence concerns the gene ALB and Sepsis.